Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab
Stopped Lack of potential study subjects due to a change of standard of care treatment outside of clinical trials.
Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation
- B-Cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia in Remission
- Acute Lymphoblastic Leukemia, Adult
Interventions
- DRUG: Blinatumomab in combination with donor lymphocyte infusion
Sponsor
Ludwig-Maximilians - University of Munich
Collaborators